Find values amidst market turmoil
There are over 100 biotech companies trading below cash, and many more down 50%+ in the last year.
See which ones will survive the bear market -- and which won't -- with screens for companies trading below or near cash, that have enough runway to wait out the bear market, and more.
Screen by development stage and therapeutic area
What are the highest and lowest valued Phase 2 oncology companies? Which neuro companies are most promising? Screen by therapeutic area and development stage in addition to financial metrics.
Track institutional holders
Who are the major institutional holders of a stock? Are they buying or selling?
See which companies have strong shareholder bases that can keep cash-burning companies alive.
Analyze investor portfolios
Which investors are buying and selling early-stage biotech stocks? Who is a long-term holder, and who focuses on short-term flips?
